Pomalidomide 2mg capsules
NHS hospitals in England used £22,328,986 of indicative cost of Pomalidomide 2mg capsules in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 4.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Pomalidomide 2mg capsules: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Pomalidomide 2mg capsules most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £1,298,443 |
| Univ Hpl B/Ham Nhs Foundation Trust | £721,719 |
| Barts Health Nhs Trust | £684,068 |
| Cambridge Univ Hosp Nhs Foundation Trust | £642,609 |
| The Royal Marsden Nhs Foundation Trust | £630,764 |
| Hull And East Yorkshire Hpls Nhs Trust | £583,806 |
| Chesterfield Royal Hospital Nhs F/T | £541,924 |
| University Hospitals Dorset Nhs Ft | £531,348 |
| Univ Hpls Bristol Nhs Foundation Trust | £528,810 |
| Derby Teaching Hospitals Nhs Found Trust | £503,004 |
The primary-care picture
Pomalidomide is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Pomalidomide medicine page.